Onkológia 4/2024
The treatment of metastatic malignant melanoma
The diagnosis of malignant melanoma still remains a potentially fatal malignancy. However, thanks to new treatment modalities such as check point inhibitors and targeted treatment - BRAF/MEK inhibitors, the mortality rate has decreased by 30% despite the increasing incidence of this diagnosis. BRAF mutation, the extent of disease, performance status and LDH level are decisive factors in the choice of treatment strategy. A special group are patients with brain metastases who have also experienced significant treatment progress thanks to immunotherapy and targeted treatment.
Keywords: immunotherapy, targeted therapy, BRAF mutation, brain metastases, treatment strategy
